Antitumor Effects of Hydromorphone on Human Gastric Cancer Cells in vitro.

Introduction: Experimental data indicate that morphine and fentanyl may have antitumor effects in gastric cancer cells (GC). Hydromorphone, as an analgesic, is used against refractory cancer pain in recent years. However, the data on hydromorphone influencing the biological characteristics of human gastric cancer cells are lacking. The aim of this study was to investigate how hydromorphone affected the growth of human gastric cancer in vitro. Material and Methods: Human GC cell lines (HGC-27, MGC-803, AGS and SGC-7901) and human gastric epithelial cells GSE-1 were exposed to various concentrations of hydromorphone (0-800µM). The cell viability, invasion and migration abilities were measured using cell counting kit-8, Transwell and wound healing assays. Apoptosis and cell cycle were evaluated by flow cytometry. Results: Hydromorphone was toxic in GSE-1 cells at the concentration 800µM. It showed enhanced antitumor effects at a longer incubation time and higher concentrations in HGC-27, MGC-803, AGS and SGC-7901 cells. Hydromorphone inhibited the progression of MGC- 803 cells by cell cycle arrest and apoptosis induction. Conclusion: Hydromorphone suppresses the proliferation of human GC cells in a dose- and time-dependent manner. That may provide a theoretical basis for the clinical application of hydromorphone in the safe and effective treatment of GC.

Association of apolipoprotein A1 -75 G/A polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery.

INTRODUCTION: Apolipoprotein A1 (apoA1) is the major apoprotein constituent of high density lipoprotein (HDL) which exerts innate protective effects in systemic inflammation. However, its role in the acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) has not been well studied. The objective of this study was to investigate the potential association between APOA1 -75 G/A polymorphism and the development of ALI after cardiopulmonary bypass (CPB) surgery. MATERIALS AND METHODS: A hospital-based case-control study was conducted in patients with ALI (n = 300), patients without ALI (n = 300) and healthy controls (n = 300). Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was applied to assess the APOA1 -75 G/A genotypes. RESULTS: Patients with ALI had a significantly higher frequency of APOA1 -75 AA genotype [odds ratio (OR) =1.75, 95% confidence interval (CI) = 1.04, 2.92; P = 0.03] than patients without ALI. APOA1 -75 AA genotype (OR =3.47, 95% CI = 1.60, 7.52; P = 0.002) and A allele (OR =1.92, 95% CI = 1.24, 2.96; P = 0.003) were the significant independent prognostic factors for the 30-day survival rate of patients with ALI after CPB surgery. CONCLUSION: Our study suggested that APOA1 -75 AA genotype was associated with a higher ALI risk after CPB surgery. Patients with the APOA1 -75 AA genotype and A allele had higher 30-day mortality of ALI after CPB surgery. Additional studies are needed to confirm this finding.